ChromaDex Corporation - CDXC STOCK NEWS

ChromaDex Corp. (NASDAQ:CDXC) announced its fourth quarter and full-year 2020 financial results, reporting total net sales of $15.4 million for Q4, an 18% increase from the previous year. Tru Niagen® sales reached $12.3 million, up 21%. The company improved its gross margin to 61.0% and reduced its net loss to ($6.1 million), resulting in a loss per share of ($0.10). Full-year net sales were $59.3 million, a 28% increase, with a net loss of ($19.9 million). The company expects continued revenue growth and margin improvement in 2021.

ChromaDex Corp. (NASDAQ:CDXC) announced that its premier NAD⁺ booster, Tru Niagen®, will be available in 3,000 Walmart stores across the U.S. starting June 2021. The product will come in two packaging options with different serving sizes and price points, also available for online purchase with same-day delivery. ChromaDex's CEO, Rob Fried, emphasized the importance of Tru Niagen® in supporting healthy aging by increasing NAD⁺ levels, which decline with age and stressors. Niagen® has been validated in nine human trials and accepted by leading regulatory agencies.

ChromaDex Corp. (NASDAQ: CDXC) will present at the Oppenheimer 31st Annual Healthcare Conference on March 17, 2021, at 3:50 PM ET. A webcast will be available on their investor relations page on www.chromadex.com. The company will also hold virtual meetings on March 16 and 17. ChromaDex focuses on healthy aging, specializing in nicotinamide adenine dinucleotide (NAD+) research and its precursor, nicotinamide riboside (NR), marketed as Niagen®. Their product Tru Niagen® is available through various retailers and online.

ChromaDex Corp. (NASDAQ:CDXC) has appointed Dr. David L. Katz to its Scientific Advisory Board. Dr. Katz is a prominent figure in nutrition and chronic disease prevention, previously serving as CEO of Diet ID and founding director of Yale’s Yale-Griffin Prevention Research Center. His expertise includes innovative research methods in preventive medicine, notably 'evidence mapping'. CEO Rob Fried expressed confidence that Dr. Katz's extensive background will enhance ChromaDex's mission to explore the health benefits of NAD⁺ and its precursors like nicotinamide riboside (NR).

ChromaDex Corp. (NASDAQ: CDXC) has published Phase 3 study results demonstrating that a nutritional protocol can reduce recovery time in mild-to-moderate COVID-19 patients by 3.5 days. Conducted at Umraniye Teaching and Research Hospital in Turkey, this double-blind trial included 309 participants and assessed the effectiveness of nicotinamide riboside (NR) and other active ingredients. The findings also indicated improved liver health and reduced inflammatory markers, supporting the potential of these metabolic activators in enhancing recovery.

ChromaDex Corp. (NASDAQ: CDXC) has announced a securities purchase agreement for a private placement of $25 million in common stock. The placement involves selling 3,846,153 shares at $6.50 each, led by a new international investor, with expected closure by February 23, 2021. The funds will enhance the growth of its flagship product, Tru Niagen^®, and support clinical research on NAD⁺ precursors. ChromaDex will enter a registration rights agreement and assures these shares are not registered under the Securities Act of 1933.

ChromaDex Corp. (NASDAQ:CDXC) will host a conference call on March 10, 2021, at 4:30 p.m. ET to discuss its fourth-quarter financial results for the period ending December 31, 2020. The results will be announced in a press release after market close. Interested participants should dial in 10 minutes prior. The toll-free and international numbers are provided in the announcement. A replay of the call will be available post-event. ChromaDex focuses on nutraceuticals and is known for its NIAGEN® ingredient, aimed at improving health as people age.

ChromaDex Corp. (NASDAQ: CDXC) announced positive results from a Phase 2 study on the effects of a nutritional protocol involving nicotinamide riboside (NR) on non-alcoholic fatty liver disease (NAFLD). The study demonstrated a significant 10% reduction in liver fat and 39% decrease in serum ALT levels among 31 overweight or obese participants. Conducted with the ChromaDex External Research Program, the findings suggest that metabolic cofactor supplementation may enhance liver health. ChromaDex has invested over $35 million in NR research and holds more than 20 patents related to its use.

ChromaDex Corp. (NASDAQ: CDXC) will present at the Benzinga Small Cap Conference on December 9, 2020, at 11:15 AM ET. This virtual event aims to connect small-cap companies with investors and traders, featuring networking and educational opportunities. ChromaDex will have a presentation available for replay on its investor relations website following the event. The company specializes in nutraceuticals, focusing on improving aging through its flagship ingredient, NIAGEN®.